One person was deemed to have white-coat hypertension (at 168/115 mm Hg) and did not require treatment. The individual reporting chest pain did not have associated electrocardiogram changes or an increase in hs-troponins to suggest acute coronary syndrome. Yet changing practice based on this case series alone would be too hasty, given that there were no pre-vaccination BP data and no clear mechanism for why someone would suddenly become hypertensive after receiving a vaccine, said Jordana Cohen, MD, MSCE, of University of Pennsylvania in Philadelphia.Īfter transfer to the ED, imaging was performed on one patient with a prior history of coiled vascular aneurysm who developed a headache after vaccination, but showed no signs of intracranial hemorrhage. "Although more data are needed to understand the extent and the mechanism of hypertension after mRNA-based vaccination, our data indicate that in elderly patients with a history of hypertension and/or significant prior cardiovascular comorbidities, pre-vaccination control of BP and post-vaccination monitoring, including symptom screening may be warranted," Meylan and colleagues suggested. Hypertension, on the other hand, has not been mentioned explicitly as an adverse event in both safety/immunogenicity trials," the authors noted.Ĭlinical trials for the vaccines included predominantly younger participants, in contrast to the older individuals who were among the first vaccinated in the real world. "The mRNA vaccines have received intense scrutiny for immediate hypersensitivity reactions in the wake of an initial report signaling 21 cases anaphylaxis. All patients recovered, but six people spent a few hours undergoing monitoring and treatment at the emergency department (ED).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |